Molecular characterization of CYP2B6 substrates

被引:39
|
作者
Ekins, Sean [1 ,2 ,3 ]
Iyer, Manisha [4 ]
Krasowski, Matthew D. [4 ]
Kharasch, Evan D. [5 ]
机构
[1] Collaborat Chem, Jenkintown, PA 19046 USA
[2] Univ Maryland, Dept Pharmaceut Sci, Baltimore, MD 21201 USA
[3] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA
[4] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA
[5] Washington Univ, Dept Anesthesiol, Div Clin & Translat Res, St Louis, MO 63110 USA
关键词
ChemSpider; CYP2B6; descriptors; properties; QSAR;
D O I
10.2174/138920008784746346
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
CYP2B6 has not been as fully characterized at the molecular level as other members of the human cytochrome P450 family. As more widely used in vitro probes for characterizing the involvement of this enzyme in the metabolism of xenobiotics have become available, the number of molecules identified as CYP2B6 substrates has increased. In this study we have analyzed the available kinetic data generated by multiple laboratories with human recombinant expressed CYP2B6 and along with calculated molecular properties derived from the ChemSpider database, we have determined the molecular features that appear to be important for CYP2B6 substrates. In addition we have applied 2D and 3D QSAR methods to generate predictive pharmacophore and 2D models. For 28 molecules with Km data, the molecular weight (mean +/- SD) is 253.78 +/- 74.03, ACD/logP is 2.68 +/- 1.51, LogD(pH5.5) is 1.51 +/- 1.43, LogD(pH7.4) is 2.02 +/- 1.25, hydrogen bond donor (HBD) count is 0.57 +/- 0.57, hydrogen bond acceptor (HBA) count is 2.57 +/- 1.37, rotatable bonds is 3.50 +/- 2.71 and total polar surface area (TPSA) is 27.63 +/- 19.42. A second set of 15 molecules without Km data possessed similar mean molecular property values. These properties are comparable to those of a set of 21 molecules used in a previous pharmacophore modeling study (Ekins et al., J Pharmacol Exp Ther 288 (1), 21-29, 1999). Only the LogD and HBD values were statistically significantly different between these different datasets. We have shown that CYP2B6 substrates are generally small hydrophobic molecules that are frequently central nervous system active, which may be important for drug discovery research.
引用
收藏
页码:363 / 373
页数:11
相关论文
共 50 条
  • [1] Effects of the CYP2B6*6 Allele on Catalytic Properties and Inhibition of CYP2B6 In Vitro: Implication for the Mechanism of Reduced Efavirenz Metabolism and Other CYP2B6 Substrates In Vivo
    Xu, Cong
    Ogburn, Evan T.
    Guo, Yingying
    Desta, Zeruesenay
    [J]. DRUG METABOLISM AND DISPOSITION, 2012, 40 (04) : 717 - 725
  • [2] CYP2B6*6 or Not CYP2B6*6-That Remains a Question for Precision Medicine and Ketamine!
    Cook-Sather, Scott D.
    Adamson, Peter C.
    Li, Jin
    Hakonarson, Hakon
    [J]. ANESTHESIOLOGY, 2016, 125 (06) : 1085 - 1087
  • [3] THE EXTENT OF INHIBITION AND INDUCTION OF CYP2B6 BY EFAVRIENZ IS CYP2B6 GENOTYPE-DEPENDENT
    Duong, A.
    Gufford, B.
    Masters, A.
    Burgess, K.
    Lu, J.
    Metzger, I.
    Desta, Z.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S36 - S36
  • [4] Analysis of clinically relevant substrates of CYP2B6 enzyme by computational methods
    Rui-Juan Niu
    Qing-Chuan Zheng
    Ji-Long Zhang
    Hong-Xing Zhang
    [J]. Journal of Molecular Modeling, 2011, 17 : 2839 - 2846
  • [5] Analysis of clinically relevant substrates of CYP2B6 enzyme by computational methods
    Niu, Rui-Juan
    Zheng, Qing-Chuan
    Zhang, Ji-Long
    Zhang, Hong-Xing
    [J]. JOURNAL OF MOLECULAR MODELING, 2011, 17 (11) : 2839 - 2846
  • [6] PharmVar GeneFocus: CYP2B6
    Desta, Zeruesenay
    El-Boraie, Ahmed
    Gong, Li
    Somogyi, Andrew A.
    Lauschke, Volker M.
    Dandara, Collet
    Klein, Kathrin
    Miller, Neil A.
    Klein, Teri E.
    Tyndale, Rachel F.
    Whirl-Carrillo, Michelle
    Gaedigk, Andrea
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (01) : 82 - 97
  • [7] Characterization of corning hepatocells for induction response to CYP2B6 inducers
    Zuo, Rongjun
    Li, Feng
    Parikh, Sweta
    Andes, Mercyanne
    Cooper, Kirsten
    Patten, Christopher J.
    [J]. DRUG METABOLISM REVIEWS, 2016, 48 : 82 - 82
  • [8] Molecular simulation study of CYP2B6 polymorphism with and without psoralen
    Lu, Nan
    Meng, Fancui
    Xu, Weiren
    Tang, Lida
    Xu, Youjun
    [J]. MOLECULAR SIMULATION, 2018, 44 (17) : 1402 - 1410
  • [9] Polymorphic CYP2B6:: molecular mechanisms and emerging clinical significance
    Zanger, Ulrich M.
    Klein, Kathrin
    Saussele, Tanja
    Blievernicht, Julia
    Hofmann, Marco H.
    Schwab, Matthias
    [J]. PHARMACOGENOMICS, 2007, 8 (07) : 743 - 759
  • [10] Further characterization of the expression in liver and catalytic activity of CYP2B6
    Ekins, S
    Vandenbranden, M
    Ring, BJ
    Gillespie, JS
    Yang, TJ
    Gelboin, HV
    Wrighton, SA
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1998, 286 (03): : 1253 - 1259